投稿信息

投稿信息
審稿費(fèi)用
暫無(wú)數(shù)據(jù)
版面費(fèi)用
15330.0元/篇 (網(wǎng)友貢獻(xiàn),非官方數(shù)據(jù))
中國(guó)人發(fā)表比例
2023年中國(guó)人文章占該期刊總數(shù)量暫無(wú)數(shù)據(jù) (2022年為18.04%)
自引率
9.1 %
年文章數(shù)
6438
期刊官網(wǎng)
點(diǎn)擊查看 (點(diǎn)擊次數(shù):11441)
投稿鏈接
點(diǎn)擊查看 (點(diǎn)擊次數(shù):5079次)
作者需知
點(diǎn)擊查看 (點(diǎn)擊次數(shù):1282次)
NCBI查詢(xún)
期刊簡(jiǎn)介
稿件收錄要求
Published by BioMed Central. ISSN: 1745-6215.

Trials is an open access, peer-reviewed, online journal that will encompass all aspects of the performance and findings of randomized controlled trials. Trials will experiment with, and then refine, innovative approaches to improving communication about trials. We are keen to move beyond publishing traditional trial results articles (although these will be included). We believe this represents an exciting opportunity to advance the science and reporting of trials. Prior to 2006, Trials was published as Current Controlled Trials in Cardiovascular Medicine (CCTCVM). All published CCTCVM articles are available via the Trials website and citations to CCTCVM article URLs will continue to be supported. The impact factor shown relates to articles published in CCTCVM during 2003-4. Making all its content open access and not retaining copyright, Trials offers a way to make data both freely available and highly visible to trialists worldwide; this will benefit the impact of your publication among peers and society. The journal has unrestricted space and takes advantage of all the technical possibilities available for electronic publishing. To date, journals have focused on reporting the results of trials, with very little coverage of why and how they are conducted. Reports of trials have been restricted both by authors and editors - both parties often select only a subset of the outcomes measured, while the latter often impose word limits on the articles published making it difficult to communicate the lessons learnt from conducting the trial, let alone include adequate details of how the trial was conducted. The Internet offers both unlimited space and interactivity, and we are keen to harness these attributes. For instance, trialists will be able to provide the detail required to be a true scientific record and do more to make the article's message comprehensible to a variety of reader groups. They will also be able to communicate not only all outcome measures, as well as varying analyses and interpretations, but also in-depth descriptions of what they did and what they learnt. This sharing of direct experience is fundamental to improving the quality and conduct of trials worldwide.
主站蜘蛛池模板: 闻喜县| 宁陕县| 鄂尔多斯市| 西林县| 微山县| 故城县| 巢湖市| 商水县| 马尔康县| 吴桥县| 迁西县| 临夏县| 江陵县| 嘉黎县| 阜平县| 永州市| 江口县| 精河县| 深泽县| 孝义市| 阿拉善盟| 旬邑县| 定边县| 彰化市| 宜兰市| 焉耆| 汝城县| 沙坪坝区| 新河县| 铜山县| 咸丰县| 汝州市| 雅江县| 杂多县| 大城县| 汉中市| 佛教| 洮南市| 广水市| 肇东市| 民县|